Early pulmonary arterial hypertension diagnosis improves five-year survival, Mayo Clinic study finds, Pulmonary Hypertension News, January 7, 2026

A recent study published in Pulmonary Circulation, summarised in an article by Andrea Lob on Pulmonary Hypertension News, found that early diagnosis of pulmonary arterial hypertension (PAH) – within six months of first healthcare contact for symptoms – improves five-year survival by 42 percentage points compared to delayed diagnosis (two years or more). Five-year survival […]

Early pulmonary arterial hypertension diagnosis improves five-year survival, Mayo Clinic study finds, Pulmonary Hypertension News, January 7, 2026 Read Post »

Simple blood test could detect pulmonary arterial hypertension, UC San Diego Health study, Nature Medicine, January 9, 2026

UC San Diego researchers published findings in Nature Medicine demonstrating that a simple blood test can detect pulmonary arterial hypertension (PAH) before it becomes life-threatening. What follows is a brief summary from an article about this study published on ABC 10 New San Diego (see link below). The test identifies a specific piece of the

Simple blood test could detect pulmonary arterial hypertension, UC San Diego Health study, Nature Medicine, January 9, 2026 Read Post »

Pulmonary hypertension, Nature Reviews Disease Primers, January 4, 2024 

This comprehensive Nature Reviews Disease Primers paper provides an authoritative overview of pulmonary hypertension (PH) globally, with particular attention to disparities between high-income (HICs) and low- and middle-income countries (LMICs). Key Points Classification and Prevalence: pulmonary hypertension is defined as mean pulmonary artery pressure >20 mmHg and comprises five groups: Group 1 (pulmonary arterial hypertension/PAH

Pulmonary hypertension, Nature Reviews Disease Primers, January 4, 2024  Read Post »

Self-management in pulmonary arterial hypertension: insights from patient interviews, Patient Preference and Adherence Journal, January 17, 2026

Twelve pulmonary arterial hypertension patients followed at the Fuwai Central China Cardiovascular Hospital in Zhengzhou City in the Henan Province, China, were interviewed to understand their self-management challenges. The findings were published in the Patient Preference and Adherence Journal on January 17, 2026, and reveal significant barriers to effective disease self-management across two main categories.

Self-management in pulmonary arterial hypertension: insights from patient interviews, Patient Preference and Adherence Journal, January 17, 2026 Read Post »

Exploring the relationship between adherence and outcomes in pulmonary arterial hypertension: A retrospective cohort study in the United States, Respiratory Medicine, January 12, 2026

Research published in Respiratory Medicine on January 12, 2026, explored adherence to pulmonary arterial hypertension-specific therapies across different therapeutic classes, identified factors associated with non-adherence and evaluated its impact on clinical outcomes. Adherence was measured by proportion of days covered (PDC) during the treatment period, defined as 60 days after first therapy until treatment discontinuation/censor.

Exploring the relationship between adherence and outcomes in pulmonary arterial hypertension: A retrospective cohort study in the United States, Respiratory Medicine, January 12, 2026 Read Post »

What life is like now: 20+ years post lung transplant, a live webinar organised by the Lung Transplant Foundation, January 16, 2026

The Lung Transplant Foundation has assembled a panel of long-term lung transplant survivors (20+ years) who share what life has been like in the decades following their successful lung transplant. This panel is a celebration of all that is possible when we say “yes” to lung transplant. 🗓️ Mark the date: January 16, 2026🕰️ 7

What life is like now: 20+ years post lung transplant, a live webinar organised by the Lung Transplant Foundation, January 16, 2026 Read Post »

Pulmonary arterial hypertension associated with exposure to toxic rapeseed oil, European Respiratory Journal Open Research, December 19, 2025

A prospective analysis from the Spanish Registry of pulmonary arterial hypertension (REHAP) examined 59 patients diagnosed with toxic oil syndrome-associated pulmonary arterial hypertension (TOS-PAH) between 1997 and 2025, providing new clinical, pathological and genetic insights into this historically significant form of drug-induced pulmonary arterial hypertension. Key findings: The patient cohort was 63% female with a

Pulmonary arterial hypertension associated with exposure to toxic rapeseed oil, European Respiratory Journal Open Research, December 19, 2025 Read Post »

The Pulmonary Hypertension Global Patient Survey:understanding the experiences and perspectives of patients, European Respiratory Journal (ERJ) Open Research, November 2025

The Pulmonary Hypertension Global Patient Survey (PH GPS), the largest survey of its kind in the pulmonary hypertension field, was collaboratively designed through a multidisciplinary consensus process and disseminated by pulmonary hypertension organizations globally. The survey analyzed data from 3,329 adult patients (mean age 52.2 years, 81.7% female) and 135 paediatric patients, examining healthcare provision,

The Pulmonary Hypertension Global Patient Survey:understanding the experiences and perspectives of patients, European Respiratory Journal (ERJ) Open Research, November 2025 Read Post »

The Pulmonary Hypertension Association of Canada: Patient Voices From Bench to Bedside and Beyond, Journal of Cardiac Failure, November 2025

The Pulmonary Hypertension Association of Canada, PHA Canada, has published an article reporting on the findings of a survey where they asked a small group of patients what they valued about having a right heart catheterization (RHC), and how they would like their care providers to share the information. The article is not open access

The Pulmonary Hypertension Association of Canada: Patient Voices From Bench to Bedside and Beyond, Journal of Cardiac Failure, November 2025 Read Post »

The acute pulmonary vasoreactivity in pulmonary arterial hypertension revisited in the contemporary era, International Journal of Cardiology Heart and Vasculature, February 2026

During right heart catheterization (RHC), the “acute vasodilator test” offers valuable insights into pulmonary circulation by evaluating vasoreactivity. A positive result identifies a rare pulmonary arterial subtype that may benefit from long-term calcium-channel blocker therapy (the so called “responders”). A recent study re-examines the applications, criteria, and objectives of acute vasodilator testing in pulmonary hypertension

The acute pulmonary vasoreactivity in pulmonary arterial hypertension revisited in the contemporary era, International Journal of Cardiology Heart and Vasculature, February 2026 Read Post »

Understanding the Connection Between Pulmonary Hypertension & Scleroderma, live webinar by the Canadian Pulmonary Hypertension Association PHA Canada, January 13, 2025

Join Dr. Nathan Hambly, a respirologist at the Firestone Institute for Respiratory Health at St. Joseph’s Healthcare, Hamilton, Canada, as he explores why pulmonary arterial hypertension happens in scleroderma, how to spot the signs early, and what care options exist today. 🗓️ January 13 | 🕐 1:30 pm EST | 💻 Online🎙️ Hosted in partnership

Understanding the Connection Between Pulmonary Hypertension & Scleroderma, live webinar by the Canadian Pulmonary Hypertension Association PHA Canada, January 13, 2025 Read Post »

Durability of sotatercept response in pulmonary arterial hypertension: Insights from extended real-world follow-up, International Journal of Cardiology, January 2, 2026

A retrospective cohort study using data from 103 healthcare organizations compared 454 pulmonary arterial hypertension patients receiving sotatercept to 963.386 pulmonary arterial hypertension patients not receiving sotatercept. After propensity score matching to balance baseline characteristics, 346 patients per group were analyzed over an average follow-up of approximately 6-8 months. The sotatercept group demonstrated dramatically lower

Durability of sotatercept response in pulmonary arterial hypertension: Insights from extended real-world follow-up, International Journal of Cardiology, January 2, 2026 Read Post »

Reflecting on 2025: Our Year in Review. Thank you for standing with us, we look forward to continuing our vital mission together in 2026.

As 2025 comes to a close, we reflect with gratitude on a year of remarkable growth and impact Our Pulmonary Hypertension Knowledge Sharing Platform, the digital hub hosting the Alliance for Pulmonary Hypertension’s activities, expanded significantly over the year, recording over 9.5k views from 4.5k visitors across 106 countries—representing significant growth compared to 2024. We

Reflecting on 2025: Our Year in Review. Thank you for standing with us, we look forward to continuing our vital mission together in 2026. Read Post »

“Wheels of Hope” – Raising Awareness for Organ Donation – end-of-year campaign recap, December 31, 2025

On October 11, 2025, the Alliance for Pulmonary Hypertension launched the inspiring “Wheels of Hope” campaign, following Czech cyclist and chef Lukáš Jakovec as he embarked on an extraordinary journey across Europe to raise awareness about organ donation and transplantation—all while cycling through some of Europe’s most challenging terrain. Key Numbers Route Highlights Starting from

“Wheels of Hope” – Raising Awareness for Organ Donation – end-of-year campaign recap, December 31, 2025 Read Post »

Flolan, the first drug to be approved for the treatment of pulmonary arterial hypertension, has been discontinued after 30 years on the market

After 30 years on the market, Flolan (epoprostenol) was discontinued in November 2025, marking the end of an era for pulmonary arterial hypertension treatment. Healthcare professionals worked throughout 2025 to transition patients to alternative therapies. Veletri, a room temperature-stable version of epoprostenol, remains available. A recent article in the News section of the US Pulmonary

Flolan, the first drug to be approved for the treatment of pulmonary arterial hypertension, has been discontinued after 30 years on the market Read Post »

Inserm, France’s National Institute of Health and Medical Research, awards its 2025 Grand Prix to Prof. Marc Humbert for his role in transforming pulmonary hypertension care

Professor Marc Humbert, one of the world’s leading specialists in pulmonary arterial hypertension (PAH), has been awarded the prestigious Inserm Grand Prize in recognition of his extraordinary career dedicated to understanding and treating this life-threatening disease. Inserm is the French National Institute of Health and Medical Research. From Orphan Disease to Hope When Prof. Humbert

Inserm, France’s National Institute of Health and Medical Research, awards its 2025 Grand Prix to Prof. Marc Humbert for his role in transforming pulmonary hypertension care Read Post »

The Pulmonary Vascular Research Institute (PVRI) 2026 Congress is taking place in Dublin from 28 January-1 February 2026

The Pulmonary Vascular Research Institute (PVRI) Congress 2026 will take place in the historic city of Dublin from 28 January – 1 February 2026. ➡️ Explore the full Congress programme at this link The first and last day (28 January and 1 February) will be satellite meetings with the main plenary sessions happening 29-31 January.

The Pulmonary Vascular Research Institute (PVRI) 2026 Congress is taking place in Dublin from 28 January-1 February 2026 Read Post »

The European Reference Network for Rare Lung Diseases (ERN Lung) to implement universal online Patient-Reported Outcome Measure, ERN-Lung Newsletter, Issue 41, December 2025

Patient-reported outcome measures (PROMs) capture patients’ own perspectives on their health and are crucial for improving care, yet they remain underused in clinical practice due to barriers like time constraints, language availability, and licensing costs. The European Reference Center for Rare Lung Diseases (ERN LUNG) is launching an ambitious initiative to implement a standardized PROM

The European Reference Network for Rare Lung Diseases (ERN Lung) to implement universal online Patient-Reported Outcome Measure, ERN-Lung Newsletter, Issue 41, December 2025 Read Post »

Male survival disadvantage in pulmonary hypertension: independent of aetiology, age, disease severity, comorbidities and treatment, EBioMedicine, December 16, 2025

The Pulmonary Vascular Research Institute (PVRI) GoDeep meta-registry integrates data from international pulmonary hypertension registries, from which 21,123 incident hemodynamically fully characterised patients were analysed to investigate the influence of sex on survival of patients. Findings revealed that male patients have significantly higher mortality rates than female patients across all types of pulmonary hypertension. This survival

Male survival disadvantage in pulmonary hypertension: independent of aetiology, age, disease severity, comorbidities and treatment, EBioMedicine, December 16, 2025 Read Post »

The Alliance for Pulmonary Hypertension’s 2025 Webinar Series: Uniting the Global Community – With Gratitude to Our Speakers and Participants

The Alliance for Pulmonary Hypertension’s quarterly webinars aim to keep the community informed and connected by examining recent advancements, emerging research, and new initiatives in pulmonary hypertension. Through a blend of expert (scientific and patient) presentations and open dialogue, these sessions encourage active participation and create space for diverse perspectives from patients, caregivers, and healthcare

The Alliance for Pulmonary Hypertension’s 2025 Webinar Series: Uniting the Global Community – With Gratitude to Our Speakers and Participants Read Post »

TRANSLATE »
Scroll to Top